Rheumatoid arthritis, other autoimmune disorders

Guidelines (21)

Certolizumab Pegol and Secukinumab for Treating Active Psoriatic Arthritis after Inadequate Response to DMARDS (TA445)

24 May 2017

Apremilast for Treating Active Psoriatic Arthritis (TA433)

22 February 2017

Certolizumab Pegol for Treating Rheumatoid Arthritis after Inadequate Response to a TNF-Alpha Inhibitor (TA415)

26 October 2016

Secukinumab for Active Ankylosing Spondylitis after Treatment with Non-Steroidal Anti-Inflammatory Drugs or TNF-Alpha Inhibitors (TA407)

28 September 2016

Belimumab for Treating Active Autoantibody-Positive Systemic Lupus Erythematosus (TA397)

22 June 2016

TNF-Alpha Inhibitors for Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis (TA383)

2 February 2016

Adalimumab, Etanercept, Infliximab, Certolizumab Pegol, Golimumab, Tocilizumab and Abatacept for Rheumatoid Arthritis Not Previously Treated with DMARDs or after Conventional DMARDs Only Have Failed (TA375)

26 January 2016

Abatacept, Adalimumab, Etanercept and Tocilizumab for Treating Juvenile Idiopathic Arthritis (TA373)

16 December 2015

Ustekinumab for Treating Active Psoriatic Arthritis (TA340 [rapid review of TA313])

8 June 2015

Rituximab in Combination with Glucocorticoids for Treating Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (TA308)

26 March 2014

Load More
Tables (1)

Table: DMARDs, a Guide to Monitoring Requirements

6 April 2017

Tests for patients on disease-modifying arthritis drugs.

Rheumatoid arthritis, other autoimmune disorders in the News

NICE approves further treatment options for psoriatic arthritis

NICE approves further treatment options for psoriatic arthritis

By Sandhiya Sodha, 25 May 2017

Certolizumab pegol (Cimzia) and secukinumab (Cosentyx) may be used within the NHS for the treatment of psoriatic arthritis when other drugs have been unsuccessful.

Methotrexate available in button-free auto-injector

Methotrexate available in button-free auto-injector

By Isabella Laws, 26 April 2017

Rheumatoid arthritis patients who struggle to use existing methotrexate self-administration devices now have the option of a button-free injector.

Baricitinib: oral rheumatoid arthritis treatment in new drug class

Baricitinib: oral rheumatoid arthritis treatment in new drug class

By Hilary Kaube, 5 April 2017

Olumiant (baricitinib) 4mg tablets are now available for the treatment of moderate-to-severe active rheumatoid arthritis (RA).

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Twitter  

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert: Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Report an adverse event